Quest Laboratories IPO Review

Quest Laboratories Ltd. manufactures a wide range of pharmaceutical products, catering to various medical needs. With trademarks like "Quest Laboratories Limited," they produce ethical, generic, and over-the-counter drugs in tablet, liquid, and ointment forms. The IPO's asking price, with an annualized FY24 earnings, reflects a P/E ratio of 15.37, while considering FY23 earnings, it stands at 31.60, indicating a fully priced issue. Over the last three years, it averaged an EPS of Rs. 3.70 and a RoNW of 32.28%. Notably, PAT margins have grown from 2% in FY21 to 12.5% in 9M-FY24, showing promising financial performance. Considering its recent profit surge from FY22, informed investors may cautiously consider moderate investment for the medium term, or can avoid the issue.